GENEVA, July 9 -- ABLYNX NV filed a patent application (EP2026/050014) for “COMPOUNDS, CONSTRUCTS AND COMPOSITIONS TARGETING TNF AND OX40L FOR USE IN THE TREATMENT OF TYPE 1 DIABETES”. With publication no. WO/2026/146204, here are the other details related to the patent application:
Kind: Initial Publication with ISR [A1]
IPC: C07K 16/18
Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).
Disclaimer: Curated by HT Syndication....